Literature DB >> 7019414

High-performance liquid chromatographic analysis of captopril in plasma.

B Jarrott, A Anderson, R Hooper, W J Louis.   

Abstract

A sensitive assay is described for quantitating plasma captopril levels. Captopril is an orally active inhibitor of angiotensin-converting enzyme. Blood from patients taking this drug was collected into tubes containing edetate and ascorbic acid, and the plasma was separated by centrifugation. After addition of an internal standard, the plasma was deproteinized and the supernate was adjusted to pH 6.5 N-(1-Pyrene)-maleimide was added to derivatize captopril and an internal standard to fluorescent adducts. These derivatives then were extracted into ethyl acetate-benzene (1:1) and separated from other derivatized thiols by high-performance liquid chromatography. The sensitivity of the assay was 150 pmoles/ml. Preliminary pharmacokinetics were obtained in patients taking captopril chronically for essential hypertension. After administration of 100 mg of captopril for patients who had fasted overnight, the plasma levels rose rapidly; peak levels were obtained at approximately 37 min. Thereafter, the plasma levels declined rapidly, and the terminal half-life was approximately 40 min. In these patients, the time course of the plasma levels did not reflect changes in blood pressure, so there appeared to be no direct relationship between plasma levels of the parent compound and blood pressure changes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7019414     DOI: 10.1002/jps.2600700622

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

Authors:  N Hockings; A A Ajayi; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

4.  Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients.

Authors:  C Richer; B Giroux; P F Plouin; B Maarek; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

5.  Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients.

Authors:  J F Giudicelli; M Chaignon; C Richer; B Giroux; J Guedon
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

Review 6.  Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.

Authors:  K L Duchin; D N McKinstry; A I Cohen; B H Migdalof
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.

Authors:  S H Kubo; R J Cody
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

8.  The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man.

Authors:  J R Wade; P A Meredith; D M Hughes; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.